Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Myanmar-Oxford Clinical Research Unit (MOCRU) and partner Medical Action Myanmar (MAM) are performing a scrub typhus survey among fever patients attending the Puta-O clinic, a small, picturesque, secluded town surrounded by snow-capped Himalayan foothills in the far north of Myanmar over 1,500 km from Yangon.

Composite photo showing a landscape around Puta-O, and the route from Yangon to the Puta-O clinic in Myanmar

Myanmar-Oxford Clinical Research Unit (MOCRU) Researcher Dr Aung Pyae Phyo recently returned from Puta-O a small, picturesque, secluded town  surrounded by snow-capped Himalayan foothills (pictured right) in the far north of Myanmar.

MOCRU and partner Medical Action Myanmar (MAM) are performing a scrub typhus survey among fever patients attending the Puta-O clinic (pictured below), which is located over 1,500 km from Yangon. In this photo, a Puta-O clinic staff member dispenses medicine to a patient. The strip above the photo shows the rapid test result of the first positive case scrub typhus case found there.

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.